Tolerability of Enteric-Coated Mycophenolate Sodium to 1 Year in Combination With Cyclosporine and Corticosteroids in Renal Transplant Recipients

Transplantation Proceedings

Volumn 38, Issue 9, 2006, Pages 2860-2863

  Rostaing, L ^a   Mourad, G ^a   Kamar, N ^a   Garrigue, V ^a   Karras, A ^a   Lefrancois N ^a   Charpentier, B ^a   Bourbigot, B ^a   Pouteil Noble, C ^a   Bayle, F ^a   Lebranchu, Y ^a   Berthoux, F ^a   Le Meur, Y ^a   Kessler, M ^a   Moulin, B ^a   Ducloux, D ^a   Delahousse, M ^a   Lang, P ^a   Merville, P ^a   Chaouche Teyara, K ^a   Legendre, C ^a   more..

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID; STEROID;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INDUCED CANCER; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKEMIA; LEUKOPENIA; LUNG CARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; TREATMENT DURATION; URINARY TRACT INFECTION;

ADRENAL CORTEX HORMONES; ADULT; CYCLOSPORINE; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; EMULSIONS; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; ISOANTIBODIES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED; TISSUE DONORS;

EID: 33750965738     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.08.119     Document Type: Article

References (13)

1. Sollinger H.W., and U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60 (1995) 225
2. Halloran P., Mathew T., Tomlanovich S., et al., The International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 63 (1997) 39
3. Van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. A randomized double-blind multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68 (1999) 261
4. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69 (2000) 2405
5. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: etiology, incidence and management. Drug Saf 24 (2001) 645
6. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200
7. Hardinger K.L., Brennan D.C., Lowell J., et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 17 (2004) 609
8. Bjarnason I. Enteric-coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc 33 (2001) 3238
9. Salvadori M., Holzer H., de Mattos A., et al., The ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231
10. Budde K., Curtis J., Knoll G., et al., ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2004) 237
11. Kamar N., Garrigue V., Karras A., et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. Am J Transplant 6 (2006) 1042
12. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31
13. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381